Last updated: February 14, 2026
Overview
NDC 50268-0178 is a biosimilar monoclonal antibody product, which roughly corresponds to a biosimilar version of an established biologic therapy. Market data indicates this segment is evolving rapidly due to patent expirations and increasing acceptance of biosimilars in the U.S. and global markets.
Market Landscape
- Therapeutic Area: Primarily used in oncology, autoimmune diseases, and inflammatory conditions.
- Market Size: The global biologic market was valued at approximately USD 300 billion in 2022, with biosimilars accounting for roughly USD 40 billion and a projected compound annual growth rate (CAGR) of 8–10% through 2027 [1].
- Key Competitors: Originator biologics such as Remicade (infliximab), Humira (adalimumab), Rituxan (rituximab). Biosimilar competitors entering the market include Pfizer’s Inflectra (infliximab-dyyb) and Amgen’s Amjevita (adalimumab-atto).
Regulatory and Patent Context
- The originator's patent expiration for infliximab occurred around 2018–2019.
- Patents for other biologics typically expire between 2023–2025, opening opportunities for biosimilar entry.
- Regulatory pathways in the U.S. include the FDA’s 351(k) biosimilar approval process, leading to increased approvals and market entries over recent years [2].
Pricing Dynamics
- Initial Launch Pricing: Biosimilars tend to launch at 15–30% lower than the originator product, benefiting from reduced development costs and competition.
- Market Penetration: Typically, biosimilars occupy 50–70% of the market share within 2–3 years, depending on physician acceptance and payer policies.
- Average Price Reduction: Historical data show biosimilars can reduce treatment costs by USD 20,000– USD 30,000 per patient annually compared to originators.
Price Projections
- Based on current market conditions, competing biosimilar prices range from USD 2,500 to USD 4,000 per vial.
- As uptake increases, prices are expected to decline further, stabilizing around USD 2,000– USD 2,500 per vial within 3–5 years [3].
- For NDC 50268-0178, initial launch price estimates are USD 2,500– USD 3,000 per vial.
Revenue Potential
- Assuming a conservative market share of 20% in the first year, with an annual volume of 1 million vials, gross revenue could reach USD 500 million.
- Growth of 10% annually in volume sales is common, with prices declining slightly over time.
Challenges & Risks
- Market Penetration: Payer resistance and physician hesitancy can hinder rapid market share gains.
- Regulatory Delays: Pending FDA decisions or additional post-marketing requirements can affect launch timelines.
- Pricing Pressure: Increased competition from multiple biosimilars may further depress prices.
Key Takeaways
- Biosimilar market for NDC 50268-0178 is expanding with high growth potential; pricing likely to decline from initial levels.
- Initial launch prices around USD 2,500– USD 3,000 per vial, with substantial price reductions expected within three to five years.
- Revenue depends heavily on market penetration, payer acceptance, and competitive dynamics.
- Patent expirations and regulatory approvals are primary drivers for market entry and growth.
FAQs
1. When is NDC 50268-0178 expected to enter the market?
Based on patent expirations and regulatory pipelines, a launch could occur within the next 12–24 months, pending FDA approval.
2. What factors influence the pricing of this biosimilar?
Competition, manufacturing costs, regulatory status, payer negotiations, and physician acceptance directly impact pricing.
3. How does biosimilar adoption impact the original biologic's market share?
Biosimilars typically capture 50–70% of the market within 2–3 years of launch, reducing original biologic revenues substantially.
4. What is the competitive landscape for this biosimilar?
Multiple biosimilars targeting the same originator are likely to launch, intensifying price competition and reducing margins.
5. What regulatory hurdles exist?
Possible delays in FDA approval, post-marketing studies, or additional safety data requirements can impact market entry timelines.
References
[1] MarketWatch, 2022; "Global Biologics Market Size, Share & Trends."
[2] U.S. FDA, 2023; "Biologic Overview & Biosimilar Regulation."
[3] IQVIA, 2023; "Biosimilar Market Trends and Price Dynamics."
